Loading
Pembrolizumab had little effect in most sarcomas, but it shrank tumours in about 40 percent of patients with undifferentiated pleomorphic sarcoma and some with dedifferentiated liposarcoma, singling out these subtypes for immunotherapy.
Phase 2 study of 86 patients with advanced soft tissue sarcoma (undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, synovial sarcoma, leiomyosarcoma) or bone sarcoma treated with pembrolizumab.
Objective response was 18 percent in soft tissue sarcoma, driven by 40 percent in undifferentiated pleomorphic sarcoma and 20 percent in dedifferentiated liposarcoma, with no responses in leiomyosarcoma and one in synovial sarcoma; bone sarcoma response was 5 percent.
PD-1 blockade is an off-label or trial option specifically for undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, not for sarcoma in general.
Shares The Lancet Oncology, Pembrolizumab.
Shares Undifferentiated pleomorphic sarcoma (UPS), The Lancet Oncology.
Shares The Lancet Oncology, Pembrolizumab.
Shares The Lancet Oncology, Pembrolizumab.
Shares The Lancet Oncology, Pembrolizumab.
Shares Undifferentiated pleomorphic sarcoma (UPS), The Lancet Oncology.